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Abstract. Although statin therapy is the standard intervention for lowering LDL cholesterol,
combination therapy may add benefits on secondary lipid parameters and enhances statin-mediated
reductions in LDL cholesterol. The present study was undertaken to investigate the effect of statins
plus omega-3 polyunsaturated fatty acids (PUFAs) on endothelial function and lipid profile in guinea
pigs with dyslipidemia and endothelial lesions. We used 14 Guinea pigs (12 weeks old) fed with a diet
containing 0,5 % cholesterol for 12 weeks and randomized in two groups: Crestor&Omacor (0,6
mg/kg rosuvastatin and 571.4 mg/kg omega-3 PUFAs) and Crestor (0,6 mg/kg rosuvastatin).
Compared to Crestor group, Omega-3 PUFAs plus rosuvastatin improved the lipid profile
(triglycerides from 94 mg/dl to 84 mg/dl and HDL cholesterol from 11 mg/dl to 23 mg/dl) and the
proportion between serum lipoprotein. Endothelial lesions were noticed in both Crestor and
Crestor&Omacor groups due to simultaneous adding of cholesterol in diet, but without observing any
difference between the two groups. Combined therapy with omega-3-PUFAs and rosuvastatin
improves lipid profile but not endothelial lesions in guinea pigs.
Keywords: polyunsaturated fatty acids, statins, diet, cardiovascular disease, combined
treatment
INTRODUCTION
Hypertriglyceridemia is a risk factor for atherosclerotic coronary heart disease. One
therapeutic option to lower TG levels is omega-3 fatty acids, which are derived from the oil of
fish and other seafood (Yokoyama, 2007; Mihaiu, 2009). Omega-3 fatty acids differ
mechanistically from other lipid-altering drugs, which helps to explain why the therapies have
complementary mechanisms of action and thus, complementary lipid benefits when
administered with statins (McKenney, 2007).
Combination therapy for the treatment of dyslipidemia and reduction of cardiovascular
risk has been demonstrated to beneficially modify the lipid profile in multiple randomized
clinical trials. The co-administration of a statin and omega-3 has complementary effects,
resulting in less entry of TG-rich VLDL into the circulation and greater hepatic uptake of
VLDL and LDL particles (Chan, 2002).
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Although statin therapy is the standard intervention for lowering LDL cholesterol,
combination therapy has demonstrated added benefits on secondary lipid parameters and
enhances statin-mediated reductions in LDL cholesterol (Meyer, 2007).
The recently completed Combination of Prescription Omega-3 with Simvastatin
(COMBOS) study confirmed that prescription omega-3 fatty acid administered in
combination with simvastatin achieves statistically significant improvements across a range of
lipid indicators beyond the LDL primary target, including triglycerides, non–high-density
lipoprotein cholesterol, and lipoprotein particle size (Davidson, 2007).
The aim of this study was to assess the effect of concomitant administration of omega-
3-acid ethyl esters, triglyceride-lowering agents, on the steady-state pharmacokinetics of
rosuvastatin.
MATERIALS AND METHODS
The experiment was conducted on 14 guinea pigs, 3 months old, divided into two
groups: Crestor&Omacor group and Crestor group. Both groups received a hyperlipidic diet,
by adding 0.5% cholesterol in the standard chow. The first treatment consists in 0.6 mg/kg/
day of rosuvastatin (Crestor) and 571.4 mg/kg/day omega-3 fatty acids (Omacor), while the
second treatment consists in 0.6 mg/kg/day of rosuvastatin (Crestor). Guinea pigs were
housed seven per cage, in a temperature-controlled environment with a 12-h light–dark cycle,
and allowed free access to food and water. Body weight was recorded once a week. The
animals were sacrificed after 12 weeks on the experimental diet.
Omega-3 fatty acids have been highly purified in a prescription formulation (Omacor;
GlaxoSmithKline, Beecham, North Carolina), which contains 465 mg eicosapentaenoic acid,
375 mg docosahexaenoic acid, and 6 IU vitamin E in each 1-g capsule.
The hyperlipidemia was assurance by the addition of cholesterol in diet (from sheep
wool powder, ~95% [GC], Sigma-Aldrich) and the standard chow for Guinea pigs was
obtained from Pannonmill Takarmany Kft., Hungary.
Biochemical determinations
Fasting serum samples were obtained for cholesterol and triglyceride determinations at
baseline and after 12 weeks on the experimental diet. The blood was collected from the retro
orbicular sinus in serum separator tubes, and centrifuged immediately. Serum was then stored
at 0-4 °C until analysis. The samples were analyzed with Konelab 20i clinical chemistry
analyzer.
Anatomopathological aspects
After 12 weeks on experimental diets, Guinea pigs were sacrificed. The liver was
removed and prepared for histological procedures. Olympus CX41 microscope with camera
was used for microscopic exam.
Statistical analysis
Data are presented as mean values. Statistical significance of experimental
observations was determined by one-way analysis of variance (ANOVA), with the level of
significance set at P<0.05.
RESULTS AND DISCUSSION
Biochemical determinations
The results of biochemical determinations are present in table 1. It may be noted
notable changes can be observed in Crestor&Omacor group on non-HDL-C fraction, which
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decrease with 37.5%, compared to only 14% in Crestor group.  Non-HDL cholesterol is an
individual lipoprotein parameters in predicting CVD in patients with diabetes. Non-HDL
cholesterol includes an assessment of all apolipoprotein B-containing lipoproteins considered
to be atherogenic, i.e., VLDL, intermediate-density lipoprotein (IDL), and LDL, and even
lipoprotein (Weiquan, 2003).
HDL cholesterol (HDL-C), a classic parameter of lipid balance, in addition to total
cholesterol, triglycerides and LDL-C, is a strong predictor of cardiovascular risk. Several
epidemiological studies have shown positive association between HDL-C level and
cardiovascular protection, its increased concentration is becoming an important therapeutic
target. Thus, is important to understand the role of HDL-C in the body and to determine
favorable and unfavorable factors that may influence this circulating lipoprotein fraction,
protective regarding cardiovascular risk. Low HDL-C level is also a major cardiovascular risk
factor, independent of other lipid fractions, but also a risk factor that contributes to the
modification of LDL-C therapeutic targets (Barter, 2005).
Is can be observed that the HDL-C levels in Crestor & Omacor group doubled after 12
weeks of simultaneous administration of both products (23 mg / dL compared to 11 mg / dL),
while in Crestor group is observed a moderate increase of this parameter ( 16 mg / dL at the
beginning and 21 mg / dL at the end of treatment).
The change in the TC:HDL-C ratio was significantly greater in the Crestor + Omacor
group than in the Crestor group (-56.6% vs -26.2%), due to both increase of HDL-C and
decrease of  non-HDL-C.
In this study addition of omega-3 fatty acids resulted in a 17% reduction in LDL
cholesterol, compared to Crestor group which presents a 40.7% reduction. In this way, the
results suggest that omega-3 fatty acids influence the activity of statins by reducing their
effect.
When rosuvastatin was administered as monotherapy, there it could be observed a
significant increase in triglycerides levels (37.83%), but in the Crestor &Omacor group this
parameter decrease with 10.6%. Thus, omega-3 fatty acids action mainly on triglycerides
level, this parameter being directly involved in the development of cardiovascular risk.
Omacor reduces triglycerides by a dual effect - reducing the synthesis and increasing the
metabolism of existing triglycerides. The synthesis of triglycerides is inhibited through
reduced production of triglycerides in the liver, as EPA and DHA are poor substrates for the
enzymes responsible for triglyceride synthesis. EPA and DHA also inhibit esterification of
other fatty acids. Omacor increases peroxisomomal beta-oxidation of fatty acids in the liver
(www.omacor.com/Home/About_Omacor/Mechanism_of_Action).
Table 1
The values of the biochemical parameters
Lipid parameter
mg/dl
Baseline End of the treatment % Change
Crestor +
Omacor
Crestor Crestor +
Omacor
Crestor Crestor +
Omacor
Crestor
Non-HDL-C 48 50 30 43 -37.5 -14
TG 94 74 84 102 -10.6 37.83
LDL-C 45 54 37 32 -17 -40.7
HDL-C 11 16 23 21 109 31,2
TC 59 66 53 64 -10.1 -3.03
TC/HDL-C 5.36 4.12 2.30 3.04 -56.6 -26.2
* Values are given as mean, in mg/dl
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Anatomopathological lesions
In figures 1 - 4 it can be seen the histological alterations in the arteries of myocardium.
In both groups it can be seen the intimae’s thickness and edema in the muscular layer and the
dilaceration of smooth muscular fibres. The reduce intensity of the lesions is due to the
protection of the two products. In this case, it can be observed that omega-3 fatty acids do not
improve statin action on tissues and cells, lesions of both groups were similar.
Fig. 1. Artery, edema in the muscular layer,
Crestor&Omacor group, PAS stain, 400X
Fig. 2. Dilaceration of smooth muscular fibres,
Crestor&Omacor group, TCM stain, 400X
Fig. 3. Artery, edema in the muscular layer, Crestor
group, PAS stain, 400X
Fig. 4. Dilaceration of smooth muscular fibres, Crestor
group, TCM stain, 200X
CONCLUSIONS
 Co-administration of omega-3 fatty acids affects blood biochemical parameters,
especially the triglycerides, their levels decrease by 10% in Crestor&Omacor group.
 Supplementation of omega-3 fatty acids changes HDL-C levels by 109% in group
Crestor&Omacor against the Crestor group where the chance is lower (31.2%).
 LDL cholesterol levels is significant changed in Crestor group towards Crestor&Omacor
group (-40.7%, respective -17%).
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 Anatomopathological lesions from both groups are the intimae’s thickness, edema in the
muscular layer and the dilaceration of smooth muscular fibres.
 Combined therapy with omega-3 polyunsaturated fatty acids and rosuvastatin do not
improves endothelial lesions in guinea pigs.
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